Cefotaxime

Author:Prof. Dr. med. Peter Altmeyer

Last updated on: 29.10.2020

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).

Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Broad-spectrum cephalosporin 3rd generation.

Half-lifeThis section has been translated automatically.

1,1–1,6 h

Spectrum of actionThis section has been translated automatically.

Bordetella pertussis, Borrelia burgdorferi, Citrobacter spp., Clostridium spp., Enterobacter spp., E. coli, Hafnia alvei, Haemophilus spp., Klebsiella spp., Moraxella spp., Morganella morganii, Neisseria spp, Peptostreptococcus spp., Prevotella spp., Proteus spp., Providencia spp., Salmonella spp., Serratia spp., Shigella spp., Staphylococcus spp., Streptococcus spp., Yersinia spp.

IndicationThis section has been translated automatically.

Severe, life-threatening respiratory tract, urinary tract, skin, soft tissue, bone and joint infections. Therapy of acute neuroborreliosis.

Dosage and method of useThis section has been translated automatically.

2 times/day 1-2 g i.v. (max. 3 times/day 2 g or 4 times/day 3 g).
Children: 50-100 mg/kg bw/day in 2-4 ED (max. 150-250 mg/kg bw/day).
Lyme disease: 2 times/day 3 g for 14-21 days.

PreparationsThis section has been translated automatically.

Cefotaxim-ratiopharm, Claforan

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer